Akram Hamdi Muhsin (1), Ammer Muhssin Hadi (2), Aiub Bassim Naji (3), Dheyaa Aldeen Alkhateeb (4)
Background: Hepatitis C virus is a major cause of post-transfusion hepatitis infection and remains a significant global health problem. Patients with thalassemia major are at high risk of HCV due to frequent blood transfusions from infected donors. Objective: To evaluate the sero positivity of HCV infection among patients aged 3 to 18 years with β-thalassemia major. Methods: A retrospective study was conducted on 254 patients (131 females, 123 males) attending the Thalassemia Center at Karbala Children's Hospital from August 2014 to March 2015. Ages ranged from 3 to 18 years. Serological viral markers for anti-HCV antibody were tested using enzyme linked immune sorbent assay. Results: Out of 254 patients, 123 (48.4%) were male and 131 (51.6%) were female. Seventeen (6.7%) were seropositive for HCV. Among patients <6 years, 1 (2.3%) was positive; in ages 6-12 years, 7 (5.3%) were positive; and above 12 years, 9 (11.5%) were infected. Blood transfusion frequency showed that 1 (2.2%) of 45 patients receiving <100 transfusions was positive, 6 (5.4%) of 111 receiving 101-200 transfusions, 6 (9.8%) of 61 receiving 201-300 transfusions, and 4 (10.8%) of 37 receiving >300 transfusions were positive. None of the 10 patients who had undergone splenectomy were infected, while 17 (7%) without splenectomy were infected. Among 59,886 volunteer blood donors in Karbala from 2012 to 2014, 54 (0.1%) were anti-HCV positive. Conclusion: Higher rates of HCV infection in older thalassemia patients with more transfusions highlight the importance of accurate blood screening techniques like PCR to prevent infections in thalassemia patients.
Highlights:
Keywords: Hepatitis C, Thalassemia Major, Blood Transfusion, Seropositivity, Pediatric Infection
Ataei B, Hashemipour M, Kassaian N, Hassannejad R, Nokhodian Z, Adibi P. "Prevalence of anti HCV infection in patients with Beta-thalassemia in Isfahan-Iran," Int. J. Prev. Med., vol. 3, Suppl. 1, p. S118, 2012.
Choo Q. L., Kuo G., Weiner A. J., et al., "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome," Science, vol. 244, p. 359, 1989.
Major M. E., Feinstone S. M., "The Molecular Virology of Hepatitis C," Hepatology, vol. 25, p. 1527, 1997.
Farci P., Alter H. J., Govindarajan S., et al., "Lack of protective immunity against reinfection with hepatitis C virus," Science, vol. 258, p. 135, 1992.
Simmonds P., "Variability of Hepatitis C Virus," Hepatology, vol. 21, p. 570, 1995.
Simmonds P., Alberti A., Alter H. J., et al., "A proposed system for the nomenclature of hepatitis C viral genotypes," Hepatology, vol. 19, p. 1321, 1994.
Simmonds P., Bukh J., Combet C., et al., "Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes," Hepatology, vol. 42, p. 962, 2005.
Lau J. Y., Davis G. L., Prescott L. E., et al., "Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States," Ann. Intern. Med., vol. 124, p. 868, 1996.
Dusheiko G., Schmilovitz-Weiss H., Brown D., et al., "Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease," Hepatology, vol. 19, p. 13, 1994.
Davis G. L., Lau J. Y., "Factors predictive of a beneficial response to therapy of hepatitis C," Hepatology, vol. 26, p. 122S, 1997.
Martinot-Peignoux M., Marcellin P., Pouteau M., et al., "Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C," Hepatology, vol. 22, p. 1050, 1995.
Resti M., Azzari C., Rossi M. E., et al., "Hepatitis C virus antibodies in a long-term follow-up of beta-thalassaemic children with acute and chronic non-A non-B hepatitis," Eur. J. Pediatr., vol. 151, p. 573, 1992.
Blanchette V. S., Vorstman E., Shore A., et al., "Hepatitis C infection in children with hemophilia A and B," Blood, vol. 78, p. 285, 1991.
Lemon S. M., Brown E. A., "Hepatitis C virus," in *Principle and Practice of Infectious Disease*, 4th ed., G. L. Mandell, J. E. Bennett, and R. Dolin, Eds. New York: Churchill Livingstone, 1995, pp. 1474–1486.
Locasciulli A., Gornati G., Tagger A., et al., "Hepatitis C virus infection and chronic liver disease in children with leukemia in long-term remission," Blood, vol. 78, p. 1619, 1991.
Ni Y. H., Chang M. H., Lue H. C., et al., "Posttransfusion hepatitis C virus infection in children," J. Pediatr., vol. 124, p. 709, 1994.
World Health Organization, "Hepatitis C – global prevalence (update)," Wkly. Epidemiol. Rec., vol. 74, pp. 425–427, 1999.
Khalifa A. S., Mitchell B. S., Watts D. M., et al., "Prevalence of hepatitis C viral antibody in transfused and nontransfused Egyptian children," Am. J. Trop. Med. Hyg., vol. 49, p. 316, 1993.
El-Raziky M. S., El-Hawary M., Esmat G., et al., "Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children," World J. Gastroenterol., vol. 13, p. 1828, 2007.
Houghton M., "Hepatitis C viruses," in *Fields Virology*, 3rd ed., B. N. Fields, D. M. Knipe, and P. M. Howley, Eds. Philadelphia: Lippincott-Raven, 1996, pp. 1035–1058.
Adinolfi L., et al., "Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity," Hepatology, vol. 33, pp. 1358–1364, 2001.
Hickman I. J., Clouston A. D., Macdonald G. A., "Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C," Gut, vol. 51, pp. 89–94, 2002.
Hourigan L., Macdonald G., Purdie D., "Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis," Hepatology, vol. 29, pp. 1215–1219, 1999.
Hsu H. H., Greenberg H. B., "Hepatitis C," in *Infectious Diseases: A Treatise of Infectious Processes*, 5th ed., Hoeprich P. D., Jordan M. C., Ronald A. R., Eds. Philadelphia: JB Lippincott Co., 1994, p. 820.
Hsu H. H., Greenberg H. B., "Hepatitis C," in *Infectious Diseases: A Treatise of Infectious Processes*, 5th ed., Hoeprich P. D., Jordan M. C., Ronald A. R., Eds. Philadelphia: JB Lippincott Co., 1994, pp. 820–825.
World Health Organization, "Hepatitis C," Fact sheet, 1997. [Online]. Available: http://www.who.int/inf-fs/en/fact164.html
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, "Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease," Morb. Mortal. Wkly. Rep., vol. 47, 1998.
Zanetti A. R., Tanzi E., Newell M. L., "Mother-to-infant transmission of hepatitis C virus," J. Hepatol., vol. 31, pp. 96–100, 1999.
Schuttler C. G., et al., "Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA," Lancet, vol. 355, pp. 41–42, 2000.
van der Poel C. L., "Hepatitis C virus and blood transfusion: past and present risks," J. Hepatol., vol. 31, pp. 101–106, 1999.
Marcellin P., "Hepatitis C: the clinical spectrum of the disease," J. Hepatol., vol. 31, Suppl. 1, p. 9, 1999.
Seeff L. B., "Natural history of hepatitis C," Hepatology, vol. 26, p. 21S, 1997.
Gerlach J. T., Diepolder H. M., Zachoval R., et al., "Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance," Gastroenterology, vol. 125, p. 80, 2003.
Loomba R., Rivera M. M., McBurney R., et al., "The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes," Aliment Pharmacol. Ther., vol. 33, p. 559, 2011.
[Anonymous], "Chronic hepatitis C in children: natural history and prognosis," Med., vol. 100, no. 2, pp. 97–102, 2009. PMID: 19350803.
González-Peralta R. P., Langham M. R. Jr., Andres J. M., et al., "Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C," J. Pediatr. Gastroenterol. Nutr., vol. 48, p. 630, 2009.
Younossi Z., McHutchison J., "Serological tests for HCV infection," Viral Hepat. Rev., vol. 2, p. 161, 1996.
Gretch D. R., "Diagnostic tests for hepatitis C," Hepatology, vol. 26, p. 43S, 1997.
Houghton M., Weiner A., Han J., et al., "Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease," Hepatology, vol. 14, p. 381, 1991.
Kao J. H., Lai M. Y., Hwang Y. T., et al., "Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay," Dig. Dis. Sci., vol. 41, p. 161, 1996.
Busch M. P., Tobler L. H., Tegtmeier G., et al., "Use of third-generation hepatitis C virus enzyme immunoassay to resolve EIA-reactive and RIBA-indeterminate blood samples," Transfusion, vol. 40, p. 10, 2000.
Uyttendaele S., Claeys H., Mertens W., et al., "Evaluation of third-generation screening and confirmatory assays for HCV antibodies," Vox Sang., vol. 66, p. 122, 1994.
Lok A. S., Chien D., Choo Q. L., et al., "Antibody response to core, envelope and nonstructural hepatitis C virus antigens," Hepatology, vol. 18, p. 497, 1993.
Pereira B. J., Milford E. L., Kirkman R. L., et al., "Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody," N. Engl. J. Med., vol. 327, p. 910, 1992.
Chevaliez S., BouvierAlias M., Brillet R., Pawlotsky J. M., "Overestimation and underestimation of hepatitis C virus RNA levels in a widely used realtime polymerase chain reaction-based method," Hepatology, vol. 46, p. 22, 2007.
Vermehren J., Kau A., Gärtner B. C., et al., "Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification," J. Clin. Microbiol., vol. 46, p. 3880, 2008.
Martinot-Peignoux M., Marcellin P., Gournay J., et al., "Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors," J. Hepatol., vol. 20, p. 676, 1994.
Regev A., Berho M., Jeffers L. J., et al., "Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection," Am. J. Gastroenterol., vol. 97, pp. 2614–2618, 2002.
Bedossa P., Dargère D., Paradis V., "Sampling variability of liver fibrosis in chronic hepatitis C," Hepatology, vol. 38, pp. 1449–1457, 2003.
Jonas M. M., Baron M. J., Bresee J. S., Schneider L. C., "Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin," Pediatrics, vol. 98, p. 211, 1996.
Wirth S., Pieper-Boustani H., Lang T., et al., "Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C," Hepatology, vol. 41, pp. 1013–1020, 2005.
Wirth S., Ribes-Koninckx C., Calzado M. A., et al., "High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin," J. Hepatol., vol. 52, pp. 501–509, 2010.
Sokal E. M., Bourgois A., Stéphenne X., et al., "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents," J. Hepatol., vol. 52, pp. 827–831, 2010.
González-Peralta R. P., Kelly D. A., Haber B., et al., "Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics," Hepatology, vol. 42, pp. 1010–1018, 2005.
Ghany M. G., Strader D. B., Thomas D. L., et al., "Diagnosis, management, and treatment of hepatitis C: an update," Hepatology, vol. 49, pp. 1335–1374, 2009.
Imran A., "Prevalence of Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus Infections among Transfusion-Dependent Pediatric Beta Thalassemia Major Patients in Karbala," Kufa Med. J., vol. 16, no. 1, pp. 154–163, 2013.
Raham T. F., Abdul Wahed S. S., Alhaddad H. N., "Prevalence of hepatitis C among patients with β-thalassemia in Diyala, Iraq," Al-Taqani J., vol. 24, no. 4, pp. 113–120, 2011.
Majeed M. N., "Prevalence of hepatitis B and hepatitis C infections among thalassemic children in Najaf city," Kufa Med. J., vol. 5, no. 1, pp. 192–196, 2002.
Al-Kubaisy W. A., Al-Naib K. T., Habib M., "Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia," East. Mediterr. Health J., vol. 12, no. 1-2, pp. 204–210, 2006.
Abed B., "Prevalence of hepatitis C virus (HCV) among thalassemia patients in Ibn-Albalady hospital," J. Al-Nahrain Univ., vol. 13, no. 1, pp. 121–126, 2010.
Boroujerdnia M., Ali M., Zadegan A., et al., "Prevalence of hepatitis C virus (HCV) among thalassemia patients in Khuzestan Province, Southwest Iran," Pak. J. Med. Sci., vol. 25, pp. 113–117, 2009.
Daw M. A., Dau A. A., "Hepatitis C virus in Arab world: a state of concern," Sci. World J., vol. 2012, Article ID 719494, pp. 1–12, 2012.
Bhavsar H., Patel K., Vegad M., et al., "Prevalence of HIV, Hepatitis B and Hepatitis C infection in Thalassemia major patients in tertiary care hospital, Gujarat," Natl. J. Integr. Res. Med., vol. 2, no. 3, pp. 47–50, 2011.
Wanachiwanawin W., Luengrojanakul P., Sirangkapracha P., et al., "Prevalence and clinical significance of hepatitis C virus infection in Thai patients with thalassemia," Int. J. Hematol., 2003.
Al-Sweedan W., et al., "Seroprevalence and genotyping of hepatitis C virus in multiple transfused Jordanian patients with B-thalassemia major," Turk J. Hematol., vol. 28, pp. 47–51, 2011.
Mansour A. K., Aly R. M., Abdelrazek S. Y., et al., "Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients," Hematol. Oncol. Stem Cell Ther., vol. 5, no. 1, pp. 54–59, 2012.
Alavian S. M., "Hepatitis C infection in Iran: a review article," Arch. Clin. Infect. Dis., vol. 4, no. 1, pp. 47–59, 2009.
Brown R. S. Jr., Gaglio P. J., "Scope of worldwide hepatitis C problem," Liver Transpl., vol. 9, Suppl. 2, pp. S10–S13, 2003.
Ansari H., Kamani H., Arbabi-Sarjo A., "Prevalence of hepatitis C and related factors among beta-thalassemia major patients in Southern Iran in 2005–2006," J. Med. Sci., vol. 7, no. 6, pp. 997–1002, 2007.
Esa Z. O., "Complications of high serum ferritin level after splenectomy in β-thalassemic patients," Kufa Med. J., vol. 12, no. 1, pp. 243–250, 2009.
Mahdaviani F., Saremi S., Rafiee M., "Prevalence of hepatitis B, C and HIV infection in thalassemic and hemophilic patients of Markazi province in 2004," Blood Sci. J. Iran, vol. 4, pp. 313–322, 2008.
Triantos C., Kourakli A., Kalafateli M., et al., "Hepatitis C in patients with β-thalassemia major: a single-centre experience," Ann. Hematol., vol. 92, no. 6, pp. 739–746, 2013.
Yapp A. R., Lindeman R., Gilroy N., et al., "Infection outcomes in splenectomized patients with hemoglobinopathies in Australia," Int. J. Infect. Dis., vol. 13, no. 6, pp. 696–700, 2009.
Vichinsky E., Levine L., Bhatia S., et al., *Standards of Care Guidelines for Thalassemia*, Children's Hospital and Research Center Oakland, 2012. [Online]. Available: http://thalassemia.com/treatment-guidelines
Jain R., Perkins J., Johnson S. T., et al., "A prospective study for prevalence and/or development of transfusion-transmitted infections in multiply transfused thalassemia major patients," Asian J. Transfus. Sci., vol. 6, no. 2, p. 151, 2012.
Choudhury N., Phadke S., "Transfusion transmitted diseases," Indian J. Pediatr., vol. 68, pp. 951–958, 2001.
Mankad G. P., Singh S. P., "Incidence of viral hepatitis in thalassemic patients as a consequence of multiple blood transfusions," Int. J. Sci. Res. Publ., vol. 116, no. 4, pp. 82–97, 2013.
Beltrán M., Navas M. C., De la Hoz F., et al., "Hepatitis C virus seroprevalence in multi-transfused patients in Colombia," J. Clin. Virol., vol. 34, Suppl. 1, pp. S33–S38, 2005.
Ocak S., Kaya H., Cetin M., et al., "Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up," Arch. Med. Res., vol. 37, pp. 895–898, 2006.
Wanachiwanawin W., Luengrojanakul P., Sirangkapracha P., et al., "Prevalence and clinical significance of hepatitis C virus infection in Thai patients with thalassemia," Int. J. Hematol., vol. 78, pp. 374–378, 2003.
Anwar M., Nadeem A., Jamal S., et al., "Effect of HCV infection on hepatic fibrosis in patients of thalassemia major," J. Coll. Physicians Surg. Pak., vol. 16, no. 3, pp. 200–203, 2006.
Riaz H., Riaz T., Khan M. U., et al., "Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan," BMC Res. Notes, vol. 4, no. 1, p. 287, 2011.
Ansar M. M., Kooloobandi A., "Prevalence of hepatitis-C virus infection in thalassemia and hemodialysis patients in North Iran, Rasht," J. Viral Hepat., vol. 9, no. 5, pp. 390–392, 2002.
Alvai S., Arzanian M. T., Hatami K., et al., "Frequency of hepatitis C in thalassemic patients and its association with liver enzyme, Mofid Hospital, Iran, 2002," Pejouhesh, vol. 29, no. 3, pp. 213–217, 2005.
Wu S. F., Peng C. T., Wu K. H., et al., "Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients," Hemoglobin, vol. 30, pp. 215–218, 2006.
Chang C. J., Ko Y. C., Liu H. W., "Serum alanine aminotransferase levels in relation to hepatitis B and C virus infections among drug abusers in an area hyperendemic for hepatitis B," Dig. Dis. Sci., vol. 45, pp. 1949–1952, 2000.
Wang C. S., Wang S. T., Chou P., "Using the prevalence of an elevated serum alanine aminotransferase level for identifying communities with a high prevalence of hepatitis C virus infection," Arch. Intern. Med., vol. 161, pp. 392–394, 2001.
Wang C. S., Wang S. T., Chang T. T., et al., "Smoking and alanine aminotransferase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression," Arch. Intern. Med., vol. 162, pp. 811–815, 2002.
Chakravarti A., Verma V., "Distribution of hepatitis C virus genotypes in beta-thalassaemic patients from Northern India," Transfus. Med., vol. 16, pp. 433–438, 2006.
Jaiswal S. P., Chitnis D. S., Jain A. K., et al., "Prevalence of hepatitis viruses among multi-transfused homogenous thalassemia patients," Hepatol. Res., vol. 19, pp. 247–253, 2001.